AR110947A1 - TREATMENT OF RETINA DEGENERATION THROUGH THE USE OF PROGENITING CELLS - Google Patents
TREATMENT OF RETINA DEGENERATION THROUGH THE USE OF PROGENITING CELLSInfo
- Publication number
- AR110947A1 AR110947A1 ARP170103380A ARP170103380A AR110947A1 AR 110947 A1 AR110947 A1 AR 110947A1 AR P170103380 A ARP170103380 A AR P170103380A AR P170103380 A ARP170103380 A AR P170103380A AR 110947 A1 AR110947 A1 AR 110947A1
- Authority
- AR
- Argentina
- Prior art keywords
- cells
- population
- derived
- postpartum
- retinal
- Prior art date
Links
- 201000007737 Retinal degeneration Diseases 0.000 title abstract 3
- 210000004027 cell Anatomy 0.000 abstract 8
- 210000000130 stem cell Anatomy 0.000 abstract 3
- 230000004258 retinal degeneration Effects 0.000 abstract 2
- 230000002207 retinal effect Effects 0.000 abstract 2
- 210000003954 umbilical cord Anatomy 0.000 abstract 2
- 101100208237 Bos taurus THBS2 gene Proteins 0.000 abstract 1
- 101150022345 GAS6 gene Proteins 0.000 abstract 1
- 102100039648 Lactadherin Human genes 0.000 abstract 1
- 101710191666 Lactadherin Proteins 0.000 abstract 1
- 108010046722 Thrombospondin 1 Proteins 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003636 conditioned culture medium Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 210000000608 photoreceptor cell Anatomy 0.000 abstract 1
- 230000001228 trophic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Reproductive Health (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Ophthalmology & Optometry (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pregnancy & Childbirth (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Se describen métodos y composiciones para tratar y reducir la degeneración de la retina mediante el uso de células progenitoras y medios acondicionados a partir de células progenitoras, tales como células derivadas del posparto. Se describen, además, factores tróficos y otros agentes segregados por las células progenitoras que protegen las células de la retina e inhiben la apoptosis de las células de la retina, tales como las células fotorreceptoras. Reivindicación 1: El uso de una población de células derivadas del posparto para tratar la degeneración de la retina; el uso comprende administrar al ojo de un sujeto una población de células derivadas del posparto, en donde la población de células segrega moléculas puente, y en donde las moléculas puente se seleccionan de MFG-E8, Gas6, TSP-1 y TSP-2. Reivindicación 3: El uso de la reivindicación 1, en donde la población de células derivadas del posparto comprende células derivadas de tejido del cordón umbilical humano aisladas a partir de tejido del cordón umbilical humano sustancialmente libre de sangre.Methods and compositions are described for treating and reducing retinal degeneration by using progenitor cells and conditioned media from progenitor cells, such as postpartum derived cells. Trophic factors and other agents secreted by progenitor cells that protect retinal cells and inhibit apoptosis of retinal cells, such as photoreceptor cells, are also described. Claim 1: The use of a population of postpartum derived cells to treat retinal degeneration; the use comprises administering to the eye of a subject a population of cells derived from the postpartum, where the population of cells secretes bridge molecules, and where the bridge molecules are selected from MFG-E8, Gas6, TSP-1 and TSP-2. Claim 3: The use of claim 1, wherein the population of postpartum derived cells comprises cells derived from human umbilical cord tissue isolated from human umbilical cord tissue substantially free of blood.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/366,947 US20170080033A1 (en) | 2014-12-16 | 2016-12-01 | Treatment of retinal degeneration using progenitor cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR110947A1 true AR110947A1 (en) | 2019-05-22 |
Family
ID=62242613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170103380A AR110947A1 (en) | 2016-12-01 | 2017-12-01 | TREATMENT OF RETINA DEGENERATION THROUGH THE USE OF PROGENITING CELLS |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR110947A1 (en) |
| TW (1) | TW201836623A (en) |
| WO (1) | WO2018102174A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8790637B2 (en) | 2003-06-27 | 2014-07-29 | DePuy Synthes Products, LLC | Repair and regeneration of ocular tissue using postpartum-derived cells |
| US10881693B2 (en) | 2019-04-09 | 2021-01-05 | Combangio, Inc. | Processes for making and using a mesenchymal stem cell derived secretome |
| JP2023521086A (en) | 2020-04-07 | 2023-05-23 | コンバンジョ・インコーポレイテッド | Freeze-dried mesenchymal stem cell-derived secretome and use thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2906293B1 (en) * | 2012-10-09 | 2018-12-12 | SanBio, Inc. | Methods and compositions for treatment of retinal degeneration |
| CN107206028A (en) * | 2014-12-05 | 2017-09-26 | 詹森生物科技公司 | Eye disorders are treated using progenitor cells |
| BR112017012581A2 (en) * | 2014-12-16 | 2017-12-26 | Janssen Biotech Inc | retinal degeneration treatment using progenitor cells |
-
2017
- 2017-11-20 WO PCT/US2017/062526 patent/WO2018102174A1/en not_active Ceased
- 2017-12-01 TW TW106142090A patent/TW201836623A/en unknown
- 2017-12-01 AR ARP170103380A patent/AR110947A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018102174A1 (en) | 2018-06-07 |
| TW201836623A (en) | 2018-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021000614A (en) | DIFFERENTIATED CELLS FROM IMMUNOENGINEERED PLURIPOTENT CELLS. | |
| MX2020005240A (en) | SYSTEMS AND METHODS FOR OCULAR LASER SURGERY AND THERAPEUTIC TREATMENTS. | |
| CO2017004715A2 (en) | Methods and formulations to treat vascular eye diseases | |
| EA201890725A1 (en) | PHARNESIDE X-RECEPTOR AGONISTS AND THEIR APPLICATION | |
| MX2023007212A (en) | EPINEPHRINE SPRAY FORMULATIONS. | |
| EA201891152A1 (en) | EXTRACELLULAR VESICULES OF NERVOUS CELLS | |
| MX2020008680A (en) | Combination therapy with apilimod and glutamatergic agents. | |
| MX378707B (en) | COMPOUNDS FOR THE TREATMENT OF OPHTHALMOLOGICAL DISEASES AND DISORDERS. | |
| MX2020005547A (en) | Modulators of complement activity. | |
| IL273531A (en) | Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases | |
| BR112019004353A2 (en) | Methods and Vectors for Treating CNS Disorders | |
| DOP2016000102A (en) | (AZA) PIRIDOPIRAZOLOPIRIMIDINONAS AND INDAZOLOPIRIMIDINONAS AND ITS USE | |
| EA201692402A1 (en) | MEDICAL FORMS FOR LOCAL APPLICATION AND THEIR USE | |
| BR112018005267A2 (en) | process for performing phototherapy or retinal photostimulation, and system for performing phototherapy or retinal photostimulation | |
| CY1124538T1 (en) | USING PRG4 TO IMPROVE DYNAMIC VISUAL ACUITY AND HIGHER-ORDER ABIRATIONS | |
| MX2020010302A (en) | Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethyl enyl)cyclopent-1-ene-1-carboxylic acid in the treatment of eye disorders. | |
| AR110947A1 (en) | TREATMENT OF RETINA DEGENERATION THROUGH THE USE OF PROGENITING CELLS | |
| MX2019004463A (en) | OPHTHALMIC FORMULATION INCLUDING LIPOSOME TRANSPORTED CYTICOLINE FOR THE TREATMENT OF GLAUCOMA. | |
| MX2023014484A (en) | Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection. | |
| ECSP15009391A (en) | siARN AND ITS USE IN THE METHODS AND COMPOSITIONS FOR THE TREATMENT AND / OR PREVENTION OF EYE DISEASES | |
| AR092842A1 (en) | TREATMENT OF OCULAR INFLAMMATORY DISEASES USING LAQUINIMOD | |
| CL2020001426A1 (en) | Topical ophthalmic composition comprising dobesilic acid to treat diseases of the posterior segment of the eye. | |
| MX2021011598A (en) | Use of mir101 or mir128 in the treatment of seizure disorders. | |
| EA202192183A1 (en) | COMPOSITIONS WITH LIPOFUSCIN REMOVAL ACTIVITY FROM RETINA CELLS | |
| EA201792603A1 (en) | ANGIOGENESIS USING STIMULATED PLACENTAL STEM CELLS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |